The FASEB Journal • Research Communication Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease Dwight D. Koeberl,*,1 Stephanie Austin,* Laura E. Case,† Edward C. Smit - Alpha-glucosidase - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-08-13 23:54:32 Rare diseases Glycogen storage disease type II Hepatology Lysosomal storage disease Acid alpha-glucosidase Salbutamol Enzyme replacement therapy Methadone Medicine Chemistry Health		The FASEB Journal • Research Communication Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease Dwight D. Koeberl,,1 Stephanie Austin, Laura E. Case,† Edward C. Smit Add to Reading List Source URL: amdapompe.ehclients.com Download Document from Source Website File Size: 274,09 KB Share Document on Facebook

	May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im DocID: 1aiEg - View Document
	Lysosomal Storage Disorder Quarterly Report PROFICIENCY TESTING Volume 3, No. 4 DocID: JlNH - View Document
	EVIDENCE REVIEW: POMPE DISEASE Prepared for: THE ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN FINAL V[removed] DocID: GbeQ - View Document
	ARTICLE The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease Paola de Filippi, PhD1, Sabrina Ravaglia, MD, PhD2, Bruno Bembi, MD3, Alfredo Costa, DocID: G7oU - View Document
	NIH Public Access Author Manuscript Am J Med Genet C Semin Med Genet. Author manuscript; available in PMC 2013 February 15. NIH-PA Author Manuscript DocID: Blkq - View Document